Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma
Table 1
Peripheral NLR/PLR and clinical characteristics of DLBCL patients.
Characteristics
Total (n=182)
PLR
NLR
⩾150(n=90)
<150(n=92)
P-value
⩾2.32(n=96)
<2.32(n=86)
P-value
Gender
0.659
0.883
Male, n (%)
96
49
47
50
46
Age
0.883
0.235
>60
90
44
46
43
47
⩽60
92
46
46
53
39
Ann Arbor stage, n (%)
0.431
0.001
I
43
21
22
13
30
II
61
26
35
28
33
III
19
9
10
12
7
IV
59
34
25
43
16
B symptoms, n (%)
0.039
0.005
Yes
35
23
12
26
9
No
147
67
80
70
77
ECOG PS, n (%)
0.032
0.048
<2
142
64
78
69
73
⩾2
40
26
14
27
13
Extranodal sites of disease, n (%)
0.285
0.002
>1
40
23
17
30
10
⩽1
142
67
75
66
76
IPI, n (%)
0.053
0.001
0
37
16
21
16
21
1
55
20
35
18
37
2
38
21
17
24
14
3
30
18
12
23
7
4
14
11
3
10
4
5
8
4
4
5
3
LDH, n (%)
0.006
0.006
⩽1 × ULN
112
46
66
50
62
>1 × ULN
70
44
26
46
24
Bone marrow involvement, n (%)
0.567
1.000
YES
13
5
8
7
6
NO
169
85
84
89
80
Pathology type
0.728
0.728
GCB subtype
43
20
23
24
19
Non-GCB subtype
139
70
69
72
67
Serum LDH level >ULN (upper limit of normal), the normal range of LDH in our center is 0-250U/L. Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase; GCB, germinal center B cell.
